DDInter573 DDInter856
A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated heparin is more specific than LMWH for thrombin. Furthermore, the effects of UH can typically be reversed by using protamine sulfate.
Dipyridamole {u} (Compound) binds {v} (Gene) ABCC4
Dipyridamole {u} (Compound) upregulates {v} (Gene) CDK6
Dipyridamole {u} (Compound) palliates {v} (Disease) coronary artery disease
Dipyridamole {u} (Compound) is included by {v} (Pharmacologic Class) Decreased Platelet Aggregation
Dipyridamole {u} (Compound) downregulates {v} (Gene) PPP2R5E
Dipyridamole {u} (Compound) causes {v} (Side Effect) Ventricular extrasystoles
Dipyridamole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Turmeric
Dipyridamole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Theophylline
Dipyridamole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ginkgo biloba
Dipyridamole {u} may lead to a major life threatening interaction when taken with {v} Ramucirumab
Dipyridamole (Compound) binds ABCC4 (Gene)
Dipyridamole (Compound) upregulates CDK6 (Gene)
Dipyridamole (Compound) palliates coronary artery disease (Disease)
Dipyridamole (Compound) is included by Decreased Platelet Aggregation (Pharmacologic Class)
Dipyridamole (Compound) downregulates PPP2R5E (Gene)
Dipyridamole (Compound) causes Ventricular extrasystoles (Side Effect)
Dipyridamole may cause a minor interaction that can limit clinical effects when taken with Turmeric
Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Theophylline
Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Ginkgo biloba
Dipyridamole may lead to a major life threatening interaction when taken with Ramucirumab